FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause
May 12, 2023FDA Approves Vyjuvek (beremagene geperpavec-svdt) Redosable Gene Therapy for theTreatment of Dystrophic Epidermolysis Bullosa
May 19, 2023May 18, 2023 - Bausch + Lomb Corporation and Novaliq GmbH have announced that the U.S. Food and Drug Administration (FDA) has approved Miebo TM (perfluorohexyloctane ophthalmic solution; formerly known as NOV03), for the treatment of the signs and symptoms of dry eye disease (DED). Miebo is the first and only FDA-approved treatment for DED that directly targets tear evaporation.
DED affects millions of Americans and is one of the most common ocular surface disorders. A leading cause of DED is excessive tear evaporation, which due to an altered tear lipid layer, is often associated with the clinical signs of Meibomian gland dysfunction (MGD). An unstable tear film triggers increased ocular surface desiccation, inflammation and damage to the ocular surface. Miebo is designed to reduce tear evaporation at the ocular surface.